CRISPR Therapeutics AG (CRSP) a Moderate Buy, Per Wall Street

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value ...

Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

Is CRISPR Therapeutics Stock Too Risky to Buy Right Now?

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

CRISPR Therapeutics (CRSP) Is Down 7.1% After Slower Casgevy Rollout and Wider 2025 Net Loss – What's Changed

CRISPR Therapeutics recently reported that rollout of its approved gene therapy Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia has been slower than hoped, contributing to a ...

Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...
Fierce Biotech

FDA fully releases clinical hold on Intellia CRISPR gene therapy trials

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.
MarketBeat on MSN

CRISPR Therapeutics gains after earnings as pipeline hope grows

CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
BioSpace

Intellia’s CRISPR Gene Therapy Free To Move Forward After FDA Fully Lifts Hold

The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme ...

After a baby became the world's first CRISPR gene editing therapy patient, CHOP wants to expand treatment to others

One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...